Leukemia Research
Volume 33, Issue 8 , Pages 1039-1046 , August 2009

The utility of flow cytometric immunophenotyping in cytopenic patients with a non-diagnostic bone marrow: A prospective study

  • Francoise Truong

      Affiliations

    • Department of Pathology, UMass Memorial Medical Center, University of Massachusetts School of Medicine, Worcester, MA, USA
    • ,
  • Brian R. Smith

      Affiliations

    • Department of Laboratory Medicine, Yale New Haven Hospital, Yale University School of Medicine, New Haven, CT, USA
    • ,
  • Dariusz Stachurski

      Affiliations

    • Department of Pathology, Rhode Island Hospital, Brown University, Providence, RI, USA
    • ,
  • Jan Cerny

      Affiliations

    • Department of Internal Medicine, UMass Memorial Medical Center, University of Massachusetts School of Medicine, Worcester, MA, USA
    • ,
  • L. Jeffery Medeiros

      Affiliations

    • Department of Hematopathology, UT MD Anderson Cancer Center, Houston, TX, USA
    • ,
  • Bruce A. Woda

      Affiliations

    • Department of Pathology, UMass Memorial Medical Center, University of Massachusetts School of Medicine, Worcester, MA, USA
    • ,
  • Sa A. Wang

      Affiliations

    • Department of Hematopathology, UT MD Anderson Cancer Center, Houston, TX, USA
    • Corresponding Author InformationCorresponding author at: Department of Hematopathology, 1515 Holcombe Boulevard, Unit 72, Houston, TX 77030-4009, USA. Tel.: +1 713 792 2603; fax: +1 713 563 3166.

Received 27 November 2008 ,Revised 11 January 2009 ,Accepted 13 January 2009.

References 

  1. Adams PF, Hendershot GE, Marano MA. Current estimates from the National Health Interview Survey, 1996. Vital Health Stat. 1999;10:1–203
  2. DeMaeyer E, Adiels-Tegman M. The prevalence of anaemia in the world. World Health Stat Q. 1985;38:302–316
  3. Dubois RW, Goodnough LT, Ershler WB, Van Winkle L, Nissenson AR. Identification, diagnosis, and management of anemia in adult ambulatory patients treated by primary care physicians: evidence-based and consensus recommendations. Curr Med Res Opin. 2006;22:385–395
  4. Goldstein KH, Abramson N. Efficient diagnosis of thrombocytopenia. Am Fam Physician. 1996;53:915–920
  5. Kuijpers TW, Weening RS, Roos D. Clinical and laboratory work-up of patients with neutrophil shortage or dysfunction. J Immunol Methods. 1999;232:211–229
  6. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292–2302
  7. WHO classification of tumours of haematopoietic and lymphoid tissues. In:  Swerdlow SH,  Campo E,  Harris NL,  Jaffe ES,  Pileri SA,  Stein H,  Thiele J,  Vardiman JW editor. World Health Organization classification of tumours. 4th ed.. Lyon: IARC Press; 2008;
  8. Gupta R, Soupir CP, Johari V, Hasserjian RP. Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation. Br J Haematol. 2007;139:265–268
  9. Kuroda J, Kimura S, Kobayashi Y, Wada K, Uoshima N, Yoshikawa T. Unusual myelodysplastic syndrome with the initial presentation mimicking idiopathic thrombocytopenic purpura. Acta Haematol. 2002;108:139–143
  10. Vardiman JW. Hematopathological concepts and controversies in the diagnosis and classification of myelodysplastic syndromes. Hematology (Am Soc Hematol Educ Program). 2006;199–204
  11. Schmitt-Graeff A, Mattern D, Kohler H, Hezel J, Lubbert M. Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis. Pathologe. 2000;21:1–15
  12. Sole F, Espinet B, Sanz GF, Cervera J, Calasanz MJ, Luno E, et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Espanol de Citogenetica Hematologica. Br J Haematol. 2000;108:346–356
  13. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108:2509–2519
  14. Konoplev S, Medeiros LJ, Lennon PA, Prajapati S, Kanungo A, Lin P. Therapy may unmask hypoplastic myelodysplastic syndrome that mimics aplastic anemia. Cancer. 2007;110:1520–1526
  15. Della Porta MG, Malcovati L, Invernizzi R, Travaglino E, Pascutto C, Maffioli M, et al. Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia. 2006;20:549–555
  16. Kussick SJ, Fromm JR, Rossini A, Li Y, Chang A, Norwood TH, et al. Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. Am J Clin Pathol. 2005;124:170–181
  17. Malcovati L, Della Porta MG, Lunghi M, Pascutto C, Vanelli L, Travaglino E, et al. Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia. 2005;19:776–783
  18. Ogata K, Kishikawa Y, Satoh C, Tamura H, Dan K, Hayashi A. Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood. 2006;108:1037–1044
  19. Stetler-Stevenson M, Arthur DC, Jabbour N, Xie XY, Molldrem J, Barrett AJ, et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood. 2001;98:979–987
  20. Wells DA, Benesch M, Loken MR, Vallejo C, Myerson D, Leisenring WM, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood. 2003;102:394–403
  21. Scott BL, Wells DA, Loken MR, Myerson D, Leisenring WM, Deeg HJ. Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood. 2008;112:2681–2686
  22. Stachurski D, Smith BR, Pozdnyakova O, Andersen M, Xiao Z, Raza A, et al. Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases: emphasis on a global evaluation and recognition of diagnostic pitfalls. Leuk Res. 2008;32:215–224
  23. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology. 2000;36:69–86
  24. Mitelman F. An International System for Human Cytogenetic Nomenclature (ISCN); 1995.
  25. Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration?. Blood. 2006;107:1747–1750
  26. Beloosesky Y, Cohen AM, Grosman B, Grinblat J. Prevalence and survival of myelodysplastic syndrome of the refractory anemia type in hospitalized cognitively different geriatric patients. Gerontology. 2000;46:323–327
  27. Tuzuner N, Cox C, Rowe JM, Watrous D, Bennett JM. Hypocellular myelodysplastic syndromes (MDS): new proposals. Br J Haematol. 1995;91:612–617
  28. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001;
  29. Birrer A, Jusufi F, Bernimoulin M, Tichelli A, Gratwohl A, Nissen-Druey C, et al. Hematopoietic progenitor cell colony growth differentiates chronic myelomonocytic leukemia from reactive monocytosis. Eur J Haematol. 2008;81:267–272
  30. Xu Y, McKenna RW, Karandikar NJ, Pildain AJ, Kroft SH. Flow cytometric analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukemia from reactive monocytosis. Am J Clin Pathol. 2005;124:799–806
  31. Matsui WH, Brodsky RA, Smith BD, Borowitz MJ, Jones RJ. Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes. Leukemia. 2006;20:458–462
  32. Maftoun-Banankhah S, Maleki A, Karandikar NJ, Arbini AA, Fuda FS, Wang HY, et al. Multiparameter flow cytometric analysis reveals low percentage of bone marrow hematogones in myelodysplastic syndromes. Am J Clin Pathol. 2008;129:300–308
  33. Matarraz S, Lopez A, Barrena S, Fernandez C, Jensen E, Flores J, et al. The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors. Leukemia. 2008;22:1175–1183
  34. Satoh C, Dan K, Yamashita T, Jo R, Tamura H, Ogata K. Flow cytometric parameters with little interexaminer variability for diagnosing low-grade myelodysplastic syndromes. Leuk Res. 2008;32:699–707
  35. van de Loosdrecht AA, Westers TM, Westra AH, Drager AM, van der Velden VH, Ossenkoppele GJ. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood. 2008;111:1067–1077
  36. Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res. 2007;31:727–736
  37. Wimazal F, Fonatsch C, Thalhammer R, Schwarzinger I, Mullauer L, Sperr WR, et al. Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface. Leuk Res. 2007;31:1461–1468

PII: S0145-2126(09)00019-8

doi: 10.1016/j.leukres.2009.01.012

Leukemia Research
Volume 33, Issue 8 , Pages 1039-1046 , August 2009

Article Tools